Basilea Pharmaceutica AG (SW:BSLN) — Market Cap & Net Worth
Market Cap & Net Worth: Basilea Pharmaceutica AG (BSLN)
Basilea Pharmaceutica AG (SW:BSLN) has a market capitalization of $686.09 Million (CHF542.68 Million) as of June 4, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #10883 globally and #132 in its home market, demonstrating a -7.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Basilea Pharmaceutica AG's stock price CHF49.85 by its total outstanding shares 12273590 (12.27 Million). Review total liabilities of Basilea Pharmaceutica AG to assess the company's total debt and financial obligations.
Basilea Pharmaceutica AG Market Cap History: 2015 to 2026
Basilea Pharmaceutica AG's market capitalization history from 2015 to 2026. Data shows change from $1.49 Billion to $773.53 Million (-6.71% CAGR).
Basilea Pharmaceutica AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Basilea Pharmaceutica AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.65x
Basilea Pharmaceutica AG's market cap is 3.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.11x
Basilea Pharmaceutica AG's market cap is 21.11 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.13 Billion | $65.98 Million | -$51.29 Million | 17.19x | N/A |
| 2017 | $1.18 Billion | $101.52 Million | -$19.36 Million | 11.60x | N/A |
| 2018 | $620.06 Million | $132.56 Million | -$31.35 Million | 4.68x | N/A |
| 2019 | $727.13 Million | $134.38 Million | -$22.42 Million | 5.41x | N/A |
| 2020 | $824.74 Million | $127.63 Million | -$14.72 Million | 6.46x | N/A |
| 2021 | $634.96 Million | $148.12 Million | -$6.83 Million | 4.29x | N/A |
| 2022 | $710.68 Million | $147.76 Million | $12.15 Million | 4.81x | 58.51x |
| 2023 | $547.75 Million | $157.63 Million | $10.45 Million | 3.47x | 52.41x |
| 2024 | $641.63 Million | $208.54 Million | $77.59 Million | 3.08x | 8.27x |
| 2025 | $848.79 Million | $232.40 Million | $40.20 Million | 3.65x | 21.11x |
Competitor Companies of BSLN by Market Capitalization
Companies near Basilea Pharmaceutica AG in the global market cap rankings as of June 4, 2026.
Key companies related to Basilea Pharmaceutica AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #581 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #602 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #581 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #602 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Basilea Pharmaceutica AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Basilea Pharmaceutica AG's market cap moved from $1.49 Billion to $ 773.53 Million, with a yearly change of -6.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF773.53 Million | -8.87% |
| 2025 | CHF848.79 Million | +32.29% |
| 2024 | CHF641.63 Million | +17.14% |
| 2023 | CHF547.75 Million | -22.93% |
| 2022 | CHF710.68 Million | +11.93% |
| 2021 | CHF634.96 Million | -23.01% |
| 2020 | CHF824.74 Million | +13.42% |
| 2019 | CHF727.13 Million | +17.27% |
| 2018 | CHF620.06 Million | -47.35% |
| 2017 | CHF1.18 Billion | +3.83% |
| 2016 | CHF1.13 Billion | -24.09% |
| 2015 | CHF1.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of Basilea Pharmaceutica AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $686.09 Million USD |
| MoneyControl | $686.09 Million USD |
| MarketWatch | $686.09 Million USD |
| marketcap.company | $686.09 Million USD |
| Reuters | $686.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more